[1]
Hill DR, Bowery NG. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain. Nature. 1981 Mar 12:290(5802):149-52
[PubMed PMID: 6259535]
[2]
Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacological reviews. 2008 Sep:60(3):243-60. doi: 10.1124/pr.108.00505. Epub 2008 Sep 12
[PubMed PMID: 18790874]
[3]
Johnston GA. Advantages of an antagonist: bicuculline and other GABA antagonists. British journal of pharmacology. 2013 May:169(2):328-36. doi: 10.1111/bph.12127. Epub
[PubMed PMID: 23425285]
[4]
Chebib M, Johnston GA. The 'ABC' of GABA receptors: a brief review. Clinical and experimental pharmacology & physiology. 1999 Nov:26(11):937-40
[PubMed PMID: 10561820]
[5]
Andrews PR, Johnston GA. GABA agonists and antagonists. Biochemical pharmacology. 1979 Sep 15:28(18):2697-702
[PubMed PMID: 40560]
[6]
Heaulme M, Chambon JP, Leyris R, Molimard JC, Wermuth CG, Biziere K. Biochemical characterization of the interaction of three pyridazinyl-GABA derivatives with the GABAA receptor site. Brain research. 1986 Oct 8:384(2):224-31
[PubMed PMID: 3022866]
[7]
Thompson SA, Wheat L, Brown NA, Wingrove PB, Pillai GV, Whiting PJ, Adkins C, Woodward CH, Smith AJ, Simpson PB, Collins I, Wafford KA. Salicylidene salicylhydrazide, a selective inhibitor of beta 1-containing GABAA receptors. British journal of pharmacology. 2004 May:142(1):97-106
[PubMed PMID: 15100159]
[8]
Simmonds MA, Turner JP. Antagonism of inhibitory amino acids by the steroid derivative RU5135. British journal of pharmacology. 1985 Mar:84(3):631-5
[PubMed PMID: 3986429]
[9]
Frølund B, Jensen LS, Storustovu SI, Stensbøl TB, Ebert B, Kehler J, Krogsgaard-Larsen P, Liljefors T. 4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology, and structure-activity relationships. Journal of medicinal chemistry. 2007 Apr 19:50(8):1988-92
[PubMed PMID: 17375905]
[10]
Luo H, Wood K, Shi FD, Gao F, Chang Y. Suramin is a novel competitive antagonist selective to α1β2γ2 GABA(A) over ρ1 GABA(C) receptors. Neuropharmacology. 2018 Oct:141():148-157. doi: 10.1016/j.neuropharm.2018.08.036. Epub 2018 Aug 30
[PubMed PMID: 30172846]
[11]
Hadingham KL, Garrett EM, Wafford KA, Bain C, Heavens RP, Sirinathsinghji DJ, Whiting PJ. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors. Molecular pharmacology. 1996 Feb:49(2):253-9
[PubMed PMID: 8632757]
[12]
Hulse G, Kelty E, Hood S, Norman A, Basso MR, Reece AS. Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System. Current pharmaceutical design. 2015:21(23):3325-42
[PubMed PMID: 26088116]
[13]
Hood SD, Norman A, Hince DA, Melichar JK, Hulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil. British journal of clinical pharmacology. 2014 Feb:77(2):285-94. doi: 10.1111/bcp.12023. Epub
[PubMed PMID: 23126253]
[14]
Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2003 Jun:18(6):683-5
[PubMed PMID: 12784272]
[15]
Rye DB, Bliwise DL, Parker K, Trotti LM, Saini P, Fairley J, Freeman A, Garcia PS, Owens MJ, Ritchie JC, Jenkins A. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. Science translational medicine. 2012 Nov 21:4(161):161ra151. doi: 10.1126/scitranslmed.3004685. Epub
[PubMed PMID: 23175709]
[16]
Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T. Treatment of premenstrual dysphoric disorder with the GABA(A) receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology. 2017 Jun:80():46-55. doi: 10.1016/j.psyneuen.2017.02.031. Epub 2017 Mar 1
[PubMed PMID: 28319848]
Level 1 (high-level) evidence